EBV VCA IgM ELISA Kit

Produktnummer ABIN1326839

Produktdetails EBV VCA IgM ELISA Kit

Target: EBV VCA IgM (Anti-Epstein-Barr Virus Viral Capsid Antigen IgM (EBV VCA IgM))

Reaktivität: Human

Nachweismethode: Colorimetric

Methodentyp: Competition ELISA

Applikation: ELISA

Verwendungszweck: Diluted patient serum (serum diluent contains sorbent to remove rheumatoid factor and human IgG interference) is added to wells coated with purified antigen. IgM specific antibody, if present, binds to the antigen. All unbound materials are washed away and the enzyme conjugate is added to bind to the antibody-antigen complex, if present. Excess enzyme conjugate is washed off and substrate is added. The plate is incubated to allow the hydrolysis of the substrate by the enzyme. The intensity of the color generated is proportional to the amount of IgM specific antibody in the sample.

Proben: Serum

Analytische Methode: Qualitative

Anwendungsinformationen

Plattentyp: Pre-coated

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Lagerung: 4 °C

Details zu EBV VCA IgM

Target: EBV VCA IgM (Anti-Epstein-Barr Virus Viral Capsid Antigen IgM (EBV VCA IgM))

Andere Bezeichnung: EBV-VCA IgM (EBV VCA IgM Produkte)

Substanzklasse: Antibody, Antibody

Hintergrund: Epstein-Barr virus (EBV) is a herpes virus known to cause infectious mononucleosis (IM). EBV infection may demonstrate a wide spectrum of clinical symptoms. The majorities of primary EBV infections are transmitted via saliva, occur during childhood, and are sub-clinical. In the U.S., 50% of the population demonstrate EBV antibodies before the age of 5 years 80% by adulthood. Transfusion-associated EBV infections have also been reported. Epstein-Barr virus has also been associated in the pathogenisis of two human cancers, Burkitt's lymphoma and nasopharyngeal carcinoma. Burkitt's lymphoma is primarily observed in Sub-Sahara Africa, especially in African children, and in New Guinea. Nasopharyngeal carcinoma is observed in Asia, most notably in Southern China.